Literature DB >> 24756010

Inflammation is not the cause of an elevated serum ferritin in non-alcoholic fatty liver disease.

Melanie D Beaton1, Subrata Chakrabarti2, Paul C Adams3.   

Abstract

BACKGROUND: In non-alcoholic fatty liver disease (NALFD), it has often been assumed that an elevation in serum ferritin is likely related to inflammation rather than iron overload.
MATERIAL AND METHODS: Patients referred with NAFLD were entered into a clinical study of phlebotomy therapy. A liver biopsy with liver iron concentration was done at entry and 6 months after phlebotomy (n = 56) until the patient had a low serum ferritin or developed anemia. Serum ferritin was compared to liver iron concentration, ESR, CRP, BMI and grade of inflammation on liver biopsy.
RESULTS: Iron removed by phlebotomy in NAFLD correlated with the decrease in serum ferritin (r = 0.57, p = 0.0014) and liver iron concentration (r = 0.57, p = 0.0013). There was no significant correlations between serum ferritin and ESR, CRP or grade of liver inflammation.
CONCLUSIONS: Serum ferritin is related to liver iron storage in NAFLD and decreasing body iron stores by phlebotomy is reflected by an appropriate decrease in serum ferritin. Inflammation is not the cause of the elevated serum ferritin in fatty liver disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24756010

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  10 in total

1.  Adipose Tissue Transferrin and Insulin Resistance.

Authors:  Donald A McClain; Neeraj K Sharma; Shalini Jain; Alexandria Harrison; Lipika N Salaye; Mary E Comeau; Carl D Langefeld; Felipe R Lorenzo; Swapan K Das
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

2.  Both hepatic and body iron stores are increased in dysmetabolic iron overload syndrome. A case-control study.

Authors:  Caroline Jézéquel; Fabrice Lainé; Bruno Laviolle; Anita Kiani; Edouard Bardou-Jacquet; Yves Deugnier
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

3.  Hepatic iron in African Americans who underwent liver biopsy.

Authors:  James C Barton; Luigi F Bertoli; Thomas J Alford; J Clayborn Barton; Corwin Q Edwards
Journal:  Am J Med Sci       Date:  2015-01       Impact factor: 2.378

4.  Porphyria cutanea tarda associated with HFE C282Y homozygosity, iron overload, and use of a contraceptive vaginal ring.

Authors:  James C Barton; Corwin Q Edwards
Journal:  J Community Hosp Intern Med Perspect       Date:  2016-02-17

Review 5.  Outcome of phlebotomy for treating nonalcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Veeravich Jaruvongvanich; Tanawan Riangwiwat; Anawin Sanguankeo; Sikarin Upala
Journal:  Saudi J Gastroenterol       Date:  2016-11       Impact factor: 2.485

6.  Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis.

Authors:  Philipp Bernhardt; Wolfgang Kratzer; Julian Schmidberger; Tilmann Graeter; Beate Gruener
Journal:  BMC Res Notes       Date:  2018-02-06

7.  Predictive Role of Interleukin-18 in Liver Steatosis in Obese Children.

Authors:  Marta Flisiak-Jackiewicz; Anna Bobrus-Chociej; Eugeniusz Tarasów; Małgorzata Wojtkowska; Irena Białokoz-Kalinowska; Dariusz Marek Lebensztejn
Journal:  Can J Gastroenterol Hepatol       Date:  2018-04-26

8.  Iron overload phenotypes and HFE genotypes in white hemochromatosis and iron overload screening study participants without HFE p.C282Y/p.C282Y.

Authors:  James C Barton; J Clayborn Barton; Ronald T Acton
Journal:  PLoS One       Date:  2022-07-27       Impact factor: 3.752

Review 9.  Hyperferritinemia-A Clinical Overview.

Authors:  Miriam Sandnes; Rune J Ulvik; Marta Vorland; Håkon Reikvam
Journal:  J Clin Med       Date:  2021-05-07       Impact factor: 4.241

10.  Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study.

Authors:  Toshio Itani; Tomoaki Ishihara
Journal:  Obes Sci Pract       Date:  2018-08-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.